Point-of-Care in France: From Legal Access to Payment
If you are a manufacturer of point-of-care testing systems seeking reimbursement in France, the 2026 reform changes the legal landscape but not the payment logic.
This guide explains how point-of-care testing in France now operates under “biologie délocalisée”, how ARS approval works, how laboratory governance shapes deployment, and how reimbursement under the NABM framework must be secured.
Executive Summary
France has expanded where certain point-of-care (POC) tests may be performed. The February 2026 reform allows defined biological analyses to be carried out outside traditional laboratories — in medical offices, health centres, EHPAD, and other approved settings under structured supervision.
This is not deregulation. It is controlled decentralisation. Legal access has widened. Governance has tightened.
For manufacturers, the opportunity is real but so are the constraints. Every remote testing site must operate under the responsibility of an accredited laboratory. Regional Health Agencies (ARS) must authorise deployment. Quality assurance is mandatory. And critically, operational permission does not automatically confer reimbursement.
In France, the right to perform a test and the right to be paid for it sit on different legal foundations.
The reform creates space for decentralised diagnostics in urgent and access-constrained settings. It does not create automatic funding. Reimbursement depends on alignment with existing nomenclature (NABM/TNB), tariff logic, laboratory billing structures, and, where applicable, policy-level inclusion decisions. Manufacturers who treat this as a commercial rollout risk rapid friction. Those who approach it as a governed service extension, anchored in laboratory partnership and territorial need, stand a stronger chance of sustainable adoption.
This guide explains:
- What the reform actually changes
- Where the legal boundaries remain
- How laboratory governance shapes deployment
- Why reimbursement must be engineered, not assumed
- And how to sequence entry without triggering structural resistance
France has opened point-of-care testing carefully.
Success now depends on understanding how to earn payment within that architecture. France Has Opened POC. Now Earn Reimbursement. This is not https://odelletechnology.com/france-tightens-the-science-of-innovation-the-new-lahn-pathway-for-advanced-diagnostics/
Who This Guide Is For
This guidance is particularly relevant for:
- Cardiac marker POC systems (e.g., troponin)
- Coagulation and INR platforms
- HbA1c and metabolic testing systems
- Infectious disease rapid diagnostics
- Decentralised antimicrobial stewardship tools
- Manufacturers expanding into primary care, EHPAD, or rural settings
What Changed and Why It Matters
Why France Is Doing This Now
The 2026 reform reflects structural pressures within the French health system:
- Territorial inequalities in laboratory access
- Emergency department congestion
- Ageing population needs, particularly in EHPAD
- Pressure for faster rule-in / rule-out diagnostics
- National antimicrobial stewardship priorities
France is decentralising access but under laboratory supervision to manage system strain without sacrificing quality control.
Why:
Adds depth.
Signals policy awareness.
Improves dwell time.
In early 2026, the French Ministry of Health amended the 2014 framework governing point-of-care (POC) testing outside accredited medical biology laboratories. This update builds on an opinion by the French National Authority for Health (HAS) issued in December 2025, which advised the Ministry on how to modernise access to urgent and decentralised diagnostics while protecting quality and patient safety.
The regulatory text published as an Order in the Journal Officiel does not open the door to unregulated testing. Rather, it extends the legally sanctioned perimeter for certain in vitro diagnostic (IVD) analyses, subject to structured governance and oversight.
1) From Lab-Only to “Delocalised” Testing
Before 2026:
- Only medical biology laboratories could perform most diagnostic testing.
- Some POC testing was permitted, but the legal framework was vague and limited in scope.
- Sites outside laboratories lacked clarity on which tests were permitted and under what conditions.
After the 2026 Order:
- The list of eligible locations for performing the analytical phase of testing outside a laboratory now includes:
- Medical offices
- Multidisciplinary local health centres
- Maternal and infant protection services
- Nursing homes (EHPAD)
- Screening and diagnosis centres
- Sexual health centres
- Medical vehicles used during patient transport
This reflects a policy shift towards decentralisation particularly in areas where laboratory access may be insufficient or where rapid results can influence urgent decisions.
2) The List of Tests Eligible for Decentralised Use
For the first time, the regulation explicitly identifies examples of tests that may be performed outside laboratories (“biologie délocalisée”) in connection with eligible locations. Examples include:
- Cardiac markers like Troponin (I or T)
- Coagulation measures such as INR and D-dimers
- HbA1c
- Lipase
- https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000053447507
- https://www.has-sante.fr/jcms/p_3806275/fr/avis-n2025-0069/ac/seap-du-18-decembre-2025-du-college-de-la-has-relatif-au-projet-d-arrete-modifiant-les-conditions-de-realisation-de-prelevements-et-d-analyses-d-examens-de-biologie-medicale-en-dehors-d-un-laboratoire-de-biologie-medicale
This is significant: it transitions from a general concept of “POC” to a defined set of legally permitted analyses. Tests outside this list cannot be assumed to be eligible simply because they are POC-capable.
3) Strong Governance Requirements
The new regulation does not treat POC sites as independent laboratories. Instead, it requires:
- A formal convention between the decentralised testing site and a responsible medical biology laboratory.
- Authorisation by the Agence Régionale de Santé (ARS) based on defined territorial and public health criteria.
- Maintenance of quality assurance mechanisms, including accreditation requirements where applicable.
In practical terms, the laboratory remains legally and technically accountable for test quality even when the analytical phase is physically outside its walls.
4) Legal Access vs Reimbursement
Crucially, the reform does not change France’s reimbursement architecture. The Order clarifies where and how tests may be legally performed, not how they will be paid for by the health insurance system (Assurance Maladie).
In France:
- Reimbursement depends on nomenclature inclusion (e.g., NABM/TNB codes).
- Legal permission to perform a test does not guarantee a funded tariff.
- Some tests may require additional evaluation or coding changes before they can be reimbursed.
This distinction is the foundation of the strategic “how-to” that follows.
Why This Matters for Manufacturers
This reform creates a regulated opportunity space but it is not a free market opening.
- Legal reach has expanded: certain POC tests can now be performed in defined non-lab settings.
- Governance has tightened: all decentralised testing must sit under laboratory oversight and ARS authorisation.
- Reimbursement remains separate: manufacturers must navigate payment architectures in addition to regulatory access.
In other words:
Access to perform testing ≠ Automatic payment
Manufacturers must navigate both legal deployment and reimbursement strategy.
How to Earn Reimbursement for POC in France
France has created a regulated opening. Success depends on sequencing correctly.
Step 1 Confirm You Are Legally Deployable
Before strategy, confirm eligibility.
Ask:
- Is the analyte/test explicitly permitted for “biologie délocalisée” in your intended setting?
- Is the device IVDR-compliant and operationally suitable for decentralised use?
- Can performance be maintained outside a laboratory environment?
If the test is not on the authorised list, you are not facing a commercial rollout.
You are facing a national policy inclusion exercise.
Do not confuse the two.
Step 2 Build the Laboratory Partnership First
Under the 2026 Order, remote sites must operate under the responsibility of a supervising medical biology laboratory.
This means:
- The lab retains accountability.
- The lab carries accreditation exposure.
- The lab influences ARS perception.
So your first strategic move is not GP sales.
It is laboratory alignment.
Prepare a laboratory engagement pack that includes:
- Analytical validation summary
- Quality assurance framework
- Training structure
- Connectivity / traceability plan
- Incident management protocol
- Clear role delineation
Make the lab feel protected.
If the lab feels exposed, rollout will quietly stall.
Step 3 Select Sites Based on Territorial Logic, Not Prestige
ARS authorisation is grounded in territorial need.
Strong early sites typically show:
- Diagnostic access gaps
- Rural or underserved geography
- Urgent clinical decision requirements
- Overloaded referral pathways
- EHPAD fragility
Weak sites:
- High-resource urban centres with easy lab access
- Commercial showcase sites without system justification
France responds to service equity, not marketing optics.
Step 4 Secure ARS Legitimacy
The Agence Régionale de Santé (ARS) is not an administrative formality.
It is the territorial steward of healthcare equilibrium.
Its mandate is to reconcile three competing forces:
- Access
- Safety
- Financial sustainability
Within each region, the ARS arbitrates between service expansion and system stability. Under the 2026 reform, decentralised biological testing is permissible but only where it demonstrably improves territorial equity without increasing systemic risk.
Authorisation is therefore discretionary. Context matters. Geography matters. Burden matters.
Your ARS dossier must read as public health economics not product strategy.
What the ARS Is Really Assessing
Behind every formal question sits a structural concern:
1. Is There a Measurable Access Friction?
Not “is your device useful?”
But:
- Is there documented delay between sampling and clinical decision?
- Does this delay generate downstream cost (transfers, admissions, repeat consultations)?
- Is there evidence of territorial laboratory saturation?
The ARS thinks in flow terms. If your deployment does not relieve friction, it creates duplication.
2. Does the Delay Translate Into System Cost or Clinical Risk?
The ARS will evaluate:
- Emergency department congestion
- Avoidable hospitalisations
- Overuse of precautionary transfers
- Antibiotic overprescription in the absence of rapid diagnostics
- Transport burden for frail populations
In economic terms, they are asking:
Does decentralisation reduce avoidable utilisation?
If the answer is unclear, authorisation weakens.
3. Is Decentralisation Justified or Merely Convenient?
Local testing must be:
- Functionally necessary
- Geographically justified
- Operationally constrained by existing infrastructure
If a fully equipped laboratory exists 15 minutes away, decentralisation requires a stronger justification than convenience.
France decentralises for necessity, not preference.
4. Does Governance Remain Intact?
Decentralisation without governance is unacceptable.
The ARS will scrutinise:
- Which accredited laboratory assumes legal responsibility?
- How is analytical quality monitored remotely?
- How are external quality assessments integrated?
- What is the escalation pathway for abnormal or discordant results?
In economic terms, this is risk containment.
The ARS must be confident that decentralisation does not externalise quality risk onto the region.
5. Are Outcomes Observable and Measurable?
Public authorisation increasingly demands metrics.
You should define in advance:
- Turnaround time delta
- Referral reduction percentage
- Hospital admission avoidance rate
- Antibiotic stewardship improvement
- Patient transport reduction
Absent measurable endpoints, decentralisation looks like structural redundancy.
6. Are Safeguards Explicit?
Safeguards must be procedural, not aspirational:
- Defined operator training cycles
- Re-certification intervals
- Device traceability and data integration
- Incident reporting pathways
- Alignment with laboratory accreditation standards
The ARS authorises controlled risk, not innovation optimism.
How to Frame the Submission
Do not present:
A device seeking regional penetration.
Present:
A structured extension of laboratory service under accredited supervision designed to correct a documented territorial inefficiency.
This distinction is decisive.
France does not reward decentralisation framed as expansion.
It supports decentralisation framed as system optimisation.
Language That Signals Maturity
Use terminology aligned with territorial governance:
- “Correction of documented diagnostic latency”
- “Laboratory-supervised decentralised execution”
- “Mitigation of avoidable secondary care utilisation”
- “Alignment with regional public health planning”
- “Quality-controlled service extension”
Avoid commercial vocabulary.
The ARS evaluates systemic coherence, not technological novelty.
The Strategic Insight
Early ARS engagement should resemble exploratory system dialogue — not submission defence.
Position the discussion as:
“We are analysing whether this laboratory-governed extension addresses a measurable territorial friction point.”
Not:
“We intend to deploy and seek validation.”
In French health economics, legitimacy precedes scale.
Scale without legitimacy is interpreted as destabilisation.
Step 5 Map the Reimbursement Architecture Early
Legal permission to perform a test does not guarantee payment.
You must determine:
- Is there an existing NABM/TNB code?
- Who invoices the lab or the remote site?
- Under what contractual structure?
- Does decentralisation affect tariff eligibility?
If you deploy before answering these questions, you risk:
Adoption without sustainable funding.
Step 6 Decide Your Economic Model
There are three realistic models in France:
The Three Ways Manufacturers Get This Wrong
- Selling directly to clinicians before securing laboratory partnership
- Deploying devices without confirming NABM billing alignment
- Scaling before ARS authorisation and territorial validation
In France, decentralisation is permitted. Deregulation is not.
Model A Within Existing Biology Acts
You operate under existing reimbursed nomenclature.
Revenue depends on laboratory partnership structure.
Model B List Expansion / New Inclusion
Requires national engagement and evidence.
Longer timeline.
Higher strategic investment.
Model C Pathway or Programme Funding
Territorial contracts or structured care pathways.
Often used in EHPAD or underserved zones.
Choose deliberately. Do not drift into one accidentally.
Step 7 Generate the Right Evidence
France will not reward: Accuracy data alone.
You need:
- Reduction in time to decision
- Avoided transfers
- Reduced hospital admissions
- Antibiotic stewardship improvements (if relevant)
- Demonstrable pathway efficiency
Evidence must be operationally legible.
If a regional payer cannot see the system impact, reimbursement support weakens.
Step 8 Scale Only After Governance and Payment Are Stable
Premature scale creates political risk.
Scale when:
- Laboratory partner is confident.
- ARS authorisation is stable.
- Billing flow is clean.
- Quality monitoring is proven.
- Outcomes data is accumulating.
France rewards disciplined expansion.
Frequently Asked Questions
Does the 2026 reform automatically grant reimbursement for POC tests in France?
No.
The February 2026 reform governs where and under what conditions biological analyses may be performed outside an accredited laboratory. It does not modify the reimbursement architecture of the French health insurance system.
In France, reimbursement for medical biology is anchored in the NABM (Nomenclature des Actes de Biologie Médicale) and associated tariff structures. Payment depends on:
- Inclusion of the act within the nomenclature
- Defined billing responsibility
- Compliance with laboratory governance requirements
Legal authorisation to perform a test under biologie délocalisée does not create a new tariff, nor does it expand existing payment codes. Reimbursement must align with existing nomenclature or undergo formal inclusion processes.
Access and payment are governed by separate legal instruments.
Can any CE-marked IVD be deployed under biologie délocalisée?
No.
CE marking under the EU IVDR confirms regulatory conformity for safety and performance. It does not determine eligibility for decentralised use within the French health system.
Deployment outside a laboratory is limited to:
- Tests explicitly authorised within the amended regulatory framework
- Defined categories of locations
- Structured supervision by a responsible laboratory
If a biomarker or analytical category is not included within the authorised scope, decentralised deployment requires national-level policy engagement and evidentiary justification. Commercial readiness alone is insufficient.
In France, conformity is necessary but policy inclusion is decisive.
Who invoices for decentralised testing?
In most cases, the supervising medical biology laboratory retains billing authority.
Because decentralised testing operates under formal convention with an accredited laboratory, the laboratory remains legally responsible for:
- Analytical oversight
- Quality assurance
- Regulatory compliance
Consequently, reimbursement typically flows through existing NABM codes billed by the laboratory.
This has commercial implications:
Manufacturers must structure agreements in a way that aligns economic incentives between the decentralised site and the supervising laboratory. Failure to align billing structures often undermines otherwise viable deployments.
Does ARS approval guarantee funding?
No.
Authorisation by the Agence Régionale de Santé (ARS) addresses territorial need, governance compliance, and public health justification. It does not create or modify reimbursement tariffs.
ARS approval confirms that decentralised testing is:
- Justified within the regional care architecture
- Supervised appropriately
- Operationally compliant
However, tariff eligibility remains governed by national reimbursement rules.
Regional legitimacy does not equal financial entitlement.
What evidence strengthens reimbursement positioning for decentralised POC?
Analytical accuracy alone is insufficient.
Reimbursement positioning in France is strengthened by evidence demonstrating:
- Reduced time to clinical decision
- Avoided hospital transfers or admissions
- Improved pathway efficiency
- Enhanced antibiotic stewardship (where relevant)
- Documented operational savings within the supervising laboratory structure
Economic legibility matters. The system must see not only that the test works, but that it improves care delivery within existing financing constraints.
Karine Levesque Rachida NAÏT Frank Swaelens Didier Tranchier Jean-François Goglin Guillaume LEVAVASSEUR Yann de CAMBOURG Silvia Martinez-Roulier Thomas Mourait Muriel JALADON Magali RICHARD Linda Nait CEDRIC VILLEMINOT Andre Darmon Sabrina SELLAM Alexandra Pruvot Tania Aydenian Mériadec Gaignard Antoine Lubineau Pierre SANCHEZ Gurtner Laure Isabelle Bikart Hélène Chautard Gabriel Roteta Marañón Marguerite BRAC DE LA PERRIERE Dina Zielinski Julien MEICHLER Isabelle Vitali Guy Eiferman Benjamin Thomas Prof. Nikos Paragios Hédi Michau – MD Cécile GATTO Anne-Marie Farouz Elise Douar Luc BERGER Bernard castells Laetitia Hans Marion Touboul Paul Recourt Jacques Bonte Sébastien Marguerès Maxime Latry Rosana Melki Romain Pochet Pascal BECACHE Jean-Philippe Bertocchio Elvira Perreaudin Sébastien Petit Bertrand SPILTHOOREN Maxime Champain Alexandre Tortel Marlène Petrolo Michèle Melhem Loïc Etienne Emmanuel Capitaine MD Philippe Fernandes, PhD Mounia Chabane de Saint Aubin Claude Lutringer Marie-Theodora Vandewiele, LL.M. Marie-Catherine THERENE Antoine Liénéré Hammama Dania Ait Mammar Sanat Patel Anne-Sophie Dubromer Krystyna HAWLENA – KRZEMIŃSKA – Sue Kovacs Etienne GLEVAREC Joy Caceres Yoann GUYMARD Anish Shindore Hervé DUTAL Alexis BOURON Zoe Delapalme Sandra Schnock Gwenaël Dhaene Alexandre Soupramanien Marion Bougerol, PhD Sylvie Pucheu Matthieu DARTUS Sabine Fossard Odile GAMEIRO Nicolas NAUDY Cecile ALLARD Anita Burgun Rahma Kechaou marie-laure ceyssat Kathryn ERNECQ Ahalya Devi M R Anissa Kebila Pharmaceutiques Karim Vassanji Rado A. Christelle Domy Marina Vasiliou Steven Haken Lionel GUERIN Lionel MARTY Henri Souchay Béatrice BACIOTTI Dr. Wolfram Schmidt Laurence Vallet Berthois Ines Ftouhi Sylvie Hirrien Mathilde Bloumine Rikard Lundvall Alvarez Gauri Nawathe Antoine Teston Laetitia Huret 💬 Digital Pharma Lab Biogen Mehdi MOURI Charlène Gautier Jan Belletti Laure SIMONOT JOUBERT Julie Wierzbicki Maxime Bonnet codoc Géraldine Marguliès Benoît Bauwens Alex Joiner, PhD DIRONA CONSULTING Gregoire Guillet Céline Cazau-Hourcade Nawel Yakoubi (MD) Bertrand Gili Claude Bertrand Mathilde DEMOUGIN Lydie ROUX Dalya PALLOT Coralie Bouillot Caroline Métais Malika de Maillard Brice de Kinkelin Pelletan Julie Thudin Rym BERGAYA Anny Tirel Alban LAURENT Sylvie Donnasson Eric Phélippeau Lilian REVERSAT Bernard Gauthier Stephanie Kervestin – Yates – Pierre Muguet Elisabeth AUVRAY Dr Thierry Marquet Valentine Bourgeois Amina Karam Nathalie Lahitte Jean Perreaud Georges Kengue Cécile Tardy-Srinivasan Marie-Suzanne CARIME Dr Solène Vo Quang Caroline Bonhomme Michaël Pressigout Pierre-Yves Brossard Dr Thibault SUTTER, PhD 🧬 Thomas Beslé Caroline Vaquet Mouna Mael-ainin Christophe Bonneton Nouara Lhocine Marzieh KOHANDANI TAFRESH Louie LYU Kathi Apostolidis Yaniss Blain Muriel Benitah Gizem Temiz, PhD Solange Roumengous Djamila Kourta Aude Selleret Béatrice Chabance, PhD Herve de Belenet John Rendu Andréa Hachem Nicolas BONNET Fabien Omhover Anne Ridel Yannick Chaudron Oriane Walkowiak Stéphanie Devolder Virginie Davergne Benjamin Grancher Clara Eynard Rotem Bar-Or François-Xavier Mouly Elie H. Assaf Dominique Patrone Marion Porche-Lesage Isabelle Antonin Virginie Chevalier Chris Ryan Thanh-Van DANG Margaux Gouysse Ludivine Videloup Valérie Mengeaud Jeremy Hamelin Mawa DIOUF Salima BOUHADDI Nathalie Wereminski Pichard Marielle Christophe Tallec Christine Cong Guo Thierry Thieffenat Isabelle Schäfer-Chassagny Anne Panchout Bernard Adrien Bougé Zuzanna Piwkowska-Zvonkine Amgen France Etienne Samain Ayoub Saanoun Karim Hatem Laure Jamot Hoang Anh PHAM Mourad Moussaoui Wiam El Abassi Ariane Giraud Eleonore DUBOIS Philippe Soulié Nick Davis Delphine El kharrat 🎯 🎯 Manon Debuigny-Cardon Christine SOUQUIERES Thi My Lan Dang Sophie Henniart Thibaut Perchet Romain Seguin Armelle Arisi Zsuzsanna Varga, PhD Sixtine Folliet Leslie Bouhan Rita Reis Aurelie Girard Mathilde Boizon Laurence Shah Christelle Desitter-Becquet Danielle Roméro Maelle Clausse Zeyd Boukhedcha Xavier Brée Corinne Cournede Carol Bereuter Céline Romiguiere Kévan Boulaire Joaquín Peñalver de Andrés, PhD Bettayeb Mohamed Said Benjamin Magnan Andrian Consulting Fanny Audibert